MYSOLINE

This brand name is authorized in Australia, Austria, France, Ireland, Malta, Mexico, Netherlands, South Africa, Spain, Turkey, United States.

Active ingredients

The drug MYSOLINE contains one active pharmaceutical ingredient (API):

1	Primidone UNII 13AFD7670Q - PRIMIDONE
	Primidone is an anticonvulsant. Although the precise mode of action of primidone is unknown, in common with other anticonvulsants, effects on the neuronal membrane particularly with respect to alteration of ionic fluxes are likely to play a fundamental role.
	Read more about Primidone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MYSOLINE Tablet	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N03AA03	Primidone	N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AA Barbiturates and derivatives
Discover more medicines within N03AA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1939C
ES	Centro de información online de medicamentos de la AEMPS	18498
FR	Base de données publique des médicaments	65201684
IE	Health Products Regulatory Authority	35300
MT	Medicines Authority	AA1340/00101, AA1343/00301, AA565/54401
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	40520
NL	Z-Index G-Standaard, PRK	1880
TR	İlaç ve Tıbbi Cihaz Kurumu	8680395500020
US	FDA, National Drug Code	66490-690, 66490-691
ZA	Health Products Regulatory Authority	B/2.5/572